Krystal Biotech, Inc. $KRYS Shares Sold by GAMMA Investing LLC

GAMMA Investing LLC decreased its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 57.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 285 shares of the company’s stock after selling 388 shares during the period. GAMMA Investing LLC’s holdings in Krystal Biotech were worth $39,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Brooklyn Investment Group increased its position in Krystal Biotech by 291.7% during the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company’s stock worth $25,000 after purchasing an additional 105 shares during the period. Twin Tree Management LP acquired a new stake in shares of Krystal Biotech in the 1st quarter worth approximately $29,000. Fifth Third Bancorp grew its holdings in shares of Krystal Biotech by 159.1% in the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock worth $31,000 after acquiring an additional 105 shares during the period. Smartleaf Asset Management LLC grew its holdings in shares of Krystal Biotech by 128.3% in the 1st quarter. Smartleaf Asset Management LLC now owns 315 shares of the company’s stock worth $58,000 after acquiring an additional 177 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Krystal Biotech in the 1st quarter worth approximately $74,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Trading Up 0.9%

Shares of KRYS opened at $183.36 on Friday. The firm has a market capitalization of $5.31 billion, a P/E ratio of 37.27 and a beta of 0.64. The stock’s fifty day simple moving average is $152.43 and its 200 day simple moving average is $151.20. Krystal Biotech, Inc. has a twelve month low of $122.80 and a twelve month high of $207.84.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.21. The business had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. Sell-side analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 13,435 shares of the firm’s stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $150.30, for a total value of $2,019,280.50. Following the transaction, the insider directly owned 1,443,276 shares of the company’s stock, valued at $216,924,382.80. This trade represents a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders sold 49,800 shares of company stock valued at $7,487,943. Company insiders own 13.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on KRYS. Chardan Capital lowered their price target on Krystal Biotech from $219.00 to $216.00 and set a “buy” rating on the stock in a report on Friday, August 22nd. Bank of America lowered their price target on Krystal Biotech from $193.00 to $192.00 and set a “buy” rating on the stock in a report on Tuesday, July 22nd. Weiss Ratings restated a “hold (c)” rating on shares of Krystal Biotech in a report on Saturday, September 27th. HC Wainwright restated a “buy” rating and issued a $240.00 price target on shares of Krystal Biotech in a report on Monday, September 15th. Finally, Citigroup restated a “neutral” rating and issued a $166.00 price target (down previously from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $209.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).